Observation on the application of patient-controlled subcutaneous analgesia after nalbuphine operation

Effects of nalbuphine subcutaneous patient-controlled analgesia on interleukin-6 and procalcitonin

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200055262

Enrollment

Unknown

Registered

2022-01-05

Start date

2022-01-06

Completion date

Unknown

Last updated

2023-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Observation group:naborphine subcutaneous continuous analgesia

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Clear communication in Chinese; 2. Those who are willing to accept the test.

Exclusion criteria

Exclusion criteria: 1. Opioid addiction or allergy; 2. Patients with central nervous system diseases; 3. Combined with heart failure or lung failure or severe damage to liver function or severe damage to renal function.

Design outcomes

Primary

Measure	Time frame
Degree of analgesia;Degree of sedation;	—

Secondary

Measure	Time frame
Sleep status score;Comfort level;	—

Countries

China

Contacts

Public ContactShi Lirong

The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology

SLR20130228@163.com+86 13015046187

Outcome results